# Xenon Pharmaceuticals Inc. (XENE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $59.75, market value $5.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Xenon Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -5.9%** (5-yr avg -5.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -59.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -88.7%**. Return on all capital, debt included, is -88.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -64.6%**. Each dollar of assets produces -64.6% of profit.

## Growth
- **EPS growth (1 yr): -44.9%**. Earnings per share fell 44.9%.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 13.42** (quick 13.42). Current assets cover the next year's liabilities 13.42 times.
- **Altman Z-score: 67.88**. A Z-score of 67.88 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Xenon Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (19 analysts). 19 analysts cover Xenon Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $81.30 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 54.6%** (YTD 33.3%, 3-mo 15.5%). The shares are up 54.6% over twelve months including dividends.
- **From 52-week high: -17.8%** (67.8% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 0.84** (volatility 60%). Beta of 0.84 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XENE · Page: https://foliofundamentals.com/stocks/xene

Not investment advice.